Enteric Disease Testing Global Market Report 2024

Enteric disease testing is essential for diagnosing diseases affecting the gastrointestinal tract, often caused by microorganisms such as viruses, bacteria, and parasites. These diseases, transmitted through contaminated food, water, or contact with infected individuals or animals, can lead to symptoms like abdominal cramping, vomiting, nausea, and anorexia, resulting in fluid and nutrient loss. Enteric disease testing employs various technologies, including diagnostic assays, rapid tests, stool specimen testing, complete blood count (CBC), blood culture tests, urine tests, antibody tests, and bone marrow tests to identify the causative agent.

The primary types of enteric diseases include bacterial enteric diseases, parasitic enteric diseases, viral enteric diseases, and others. Bacterial pathogens such as Salmonella, Campylobacter, Shigella, Clostridium difficile, and various strains of E. coli are common contributors to enteric diseases. Different testing technologies, including traditional methods, rapid tests, convenience-based tests, polymerase chain reaction (PCR), immunoassays, chromatography, spectrometry, and others, are employed for accurate diagnosis. These tests are conducted in various healthcare settings, including hospitals, research centers, clinics, and other medical facilities.

The enteric disease testing market research report is one of a series of new reports that provides enteric disease testing market statistics, including enteric disease testing industry global market size, regional shares, competitors with a enteric disease testing market share, detailed enteric disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the enteric disease testing industry. This enteric disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The enteric disease testing market size has grown strongly in recent years. It will grow from $4.33 billion in 2023 to $4.59 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The expansion observed in the historical period can be attributed to several factors, including growing concerns about water and food safety, a rise in outbreaks and epidemics, the globalization of the food supply chain, an increase in travel-related infections, and the implementation of regulatory standards. These elements collectively contributed to the overall growth observed during that timeframe.

The enteric disease testing market size is expected to see strong growth in the next few years. It will grow to $5.81 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The anticipated growth in the forecast period can be attributed to several key factors, including the integration of telemedicine and remote monitoring in healthcare, the effects of climate change on disease patterns, increased collaboration across sectors, concerns related to antimicrobial resistance, and the emergence of new enteric pathogens. Noteworthy trends expected in this period encompass the adoption of molecular diagnostics, the integration of digital health solutions, the application of artificial intelligence (AI) and machine learning in diagnostics, increased use of syndromic testing, and the expansion of point-of-care testing. These trends are poised to significantly impact and contribute to the projected growth and evolution of the enteric disease testing industry in the forecasted period.

The anticipated rise in cases of diarrhea and hemolytic urea syndrome (HUS) is poised to drive the growth of the enteric disease testing market. Diarrheal diseases, often caused by consuming contaminated food and water, are a significant health concern globally. Additionally, HUS, a disorder impacting blood and blood vessels, particularly in children with diarrhea, further contributes to the demand for testing solutions. According to the Centers for Disease Control and Prevention, diarrhea ranks as the second leading cause of mortality among children under the age of 5, resulting in 801 thousand deaths annually, making up one out of every nine child deaths. As these enteric diseases continue to prevail, the market for enteric disease testing is expected to witness growth.

The increasing consumption of frozen food is anticipated to be a driving factor for the enteric disease testing market. Frozen food, while a convenient option, can sometimes pose a risk of foodborne illnesses, including enteric diseases, if not handled, stored, or cooked properly. In 2022, the American Frozen Food Institute reported a notable 8.6% increase in frozen food sales, reaching $72.2 billion. The growing popularity of frozen food products underscores the importance of rigorous testing measures to ensure food safety, consequently fueling the demand for enteric disease testing solutions.

A notable trend in the enteric disease testing market is the establishment of new laboratories by companies to offer food-testing services. Key players in the market are strategically opening new laboratories to enhance their capacity for providing quality testing services, especially in the food manufacturing, retail, and hospitality segments. For example, SGS Group, a Switzerland-based company specializing in verification, testing, inspection, and certification services, announced the opening of the NATA ISO17025 Accredited Laboratory in June 2021. This addition to the SGS group aims to deliver internationally recognized quality testing services to address the rising demand for enteric disease testing in the food industry.

Leading companies in the enteric disease testing market are strategically focusing on the development of products capable of simultaneously measuring multiple biomarkers, aiming to gain a competitive advantage. The significance of enteric disease testing devices that can concurrently assess multiple biomarkers lies in their ability to diagnose and monitor various gastrointestinal conditions, ultimately enhancing patient care. A notable example is Quansys Biosciences Inc., which, in collaboration with the global health organization PATH, introduced the Q-Plex Human Environmental Enteric Dysfunction (11-Plex) diagnostic tool in July 2021. Designed to expedite interventions for Environmental Enteric Dysfunction (EED), this tool utilizes a chemiluminescent assay to simultaneously assess eleven biomarkers or analytes. It proves instrumental in researching and managing EED, offering an economical solution for profiling nutritional and inflammatory biomarkers associated with the condition.

In a strategic move, Thermo Fisher Scientific, a global laboratory equipment manufacturing company, acquired Mesa Biotech in February 2021. This acquisition enables Thermo Fisher to leverage Mesa's innovative point-of-care molecular diagnostic platform, combining their expertise to deliver cost-efficient and optimal solutions to address patients' needs. Mesa Biotech, as a leading player in the enteric disease testing market, contributes to the broader capabilities of Thermo Fisher Scientific, enhancing their position in the industry.

Major companies operating in the enteric disease testing market include Becton Dickinson and Company, Biomerica Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Cepheid Inc., Coris Bioconcept, DiaSorin Molecular LLC, MMeridian Life Science Inc., Quest Consumer Inc., Trinity Biotech plc., Abbott Laboratories, GlaxoSmithKline Plc., Sanofi India Limited., Bayer HealthCare Pharmaceuticals LLC, Fisher Scientific Inc., Bio Rad Laboratories Pvt Ltd., Alere Inc., 3M Company., ALS Limited, Asure Quality, Bureau Veritas, Meridian Bioscience Inc., Hologic Inc., Luminex Corporation, Nanosphere Inc., Quidel Corporation, Roche Diagnostics, Siemens Healthcare Diagnostics Inc., Vela Diagnostics, GenMark Diagnostics, Illumina Inc., BioFire Diagnostics LLC, Veredus Laboratories Pte Ltd.

North America was the largest region in the enteric disease testing market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the global enteric disease testing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the enteric disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The enteric disease testing market includes revenues earned by entities by amebiasis, campylobacteriosis, cryptosporidiosis, and cyclosporiasis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.